{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005265","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.571280+00:00","generated_at":"2026-05-17T15:58:29.684386+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioCryst's Chief R&D Officer resigns after CEO selection process; to depart Sep 1, 2025","bullets":["Dr. Helen Thackray resigns as Chief R&D Officer effective Sep 1, 2025, after not being selected as next CEO.","Separation benefits include 1 year base salary, 2025 bonus (actual and target), 12 months health coverage, outplacement, accelerated equity vesting.","Consulting agreement for transition through Dec 31, 2025: monthly fee $12,500, continued equity vesting during period.","No disagreement cited with Board or management regarding company operations or policies."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005265","json":"https://secwatch.observer/filing/0001171843-25-005265.json","markdown":"https://secwatch.observer/filing/0001171843-25-005265.md","text":"https://secwatch.observer/filing/0001171843-25-005265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325005265/0001171843-25-005265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325005265/f8k_081125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:58:29.684386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}